← All trials
NCT00331006
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2006
- Primary completion
- Nov 1, 2010
- Completion date
- Jan 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 23
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- New England Research InstitutesLead sponsor
- Blood Center of WisconsinOverall official - principal investigator
- University of OklahomaOverall official - principal investigator
- Rush UniversityOverall official - principal investigator
- University of North Carolina at Chapel HillOverall official - principal investigator
- University of PennsylvaniaOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Hemophilia Center of Western PennsylvaniaOverall official - principal investigator
- Cook Children's Medical CenterOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- Tulane UniversityOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- GenentechCollaborator
- Harvard UniversityOverall official - principal investigator
- University of California, IrvineOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.